Alps Advisors Inc Crispr Therapeutics Ag Transaction History

Alps Advisors Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $205,845 - $282,254	-3,369 Reduced 7.33%	42,581 $2.78 Million
Q2 2022 Aug 11, 2022	BUY	$43.23 - $73.83 $1.99 Million - $3.39 Million	45,950 New	45,950 $2.79 Million
Q2 2019 Aug 07, 2019	SELL	$35.45 - $48.2 $4.44 Million - $6.03 Million	-125,116 Closed	0 $0
Q1 2019 May 01, 2019	BUY	$28.02 - $40.87 $177,254 - $258,543	6,326 Added 5.33%	125,116 $4.47 Million
Q4 2018 Feb 04, 2019	BUY	$22.73 - $42.34 $2.7 Million - $5.03 Million	118,790 New	118,790 $3.39 Million

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.